Iron Triangle Partners LP — 13F Holdings & Portfolio
CIK 1779763 · latest 13F-HR filed 2026-02-17
Iron Triangle Partners LP manages $874.7M in 13F-reported U.S. long-equity assets across 27 reported positions as of its 2025-12-31 13F-HR filing. Its largest disclosed positions are CRL (8.66%), ISRG (6.12%), RGEN (6.00%). Quarter over quarter (versus its 2025-09-30 filing) the fund opened 16 new positions and exited 14; 8 existing positions rose in reported value and 2 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-02-17
vs 2025-09-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q4 25Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q3 25 → Q4 25Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
2 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 53.2%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 24, 2026.
1ST FLOOR
COS COB, CT 06807
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| IRON TRIANGLE PARTNERS GP LLC Control | GENERAL PARTNER since Feb 2019 | Less than 5% | Domestic Entity |
| MOLLOY, KEVIN, THOMAS Control | LIMITED PARTNER since Feb 2019 | 75% or more | Individual |
| O'BRIEN, MICHAEL, JOHN Control | CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER since Apr 2019 | Less than 5% | Individual |
| MOLLOY, KEVIN, THOMAS Control Indirect owner via IRON TRIANGLE PARTNERS GP LLC | MANAGING MEMBER since Feb 2019 | 75% or more | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- CHARLES RIV LABS INTL INC$33.8M +80.6%
- JAZZ PHARMACEUTICALS PLC$29.9M +151.2%
- VERACYTE INC$24.6M +147.9%
- REPLIGEN CORP$16.4M +45.5%
- DOXIMITY INC$15.0M +97.9%
New Positions
- INTUITIVE SURGICAL INC$53.5M
- BOSTON SCIENTIFIC CORP$40.1M
- WATERS CORP$39.9M
- BRUKER CORP$37.4M
- VERTEX PHARMACEUTICALS INC$34.9M
Exited Positions
- DEXCOM INC$57.2M
- ABBVIE INC$46.4M
- MEDTRONIC PLC$43.2M
- GLAUKOS CORP$28.0M
- TENET HEALTHCARE CORP$27.9M
Iron Triangle Partners LP Holdings (2025-12-31)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CHARLES RIV LABS INTL INC | CRL | 159864107 | $75.7M | 8.66% | 379,728 | SH |
| 2 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $53.5M | 6.12% | 94,459 | SH |
| 3 | REPLIGEN CORP | RGEN | 759916109 | $52.5M | 6.00% | 320,474 | SH |
| 4 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $49.7M | 5.68% | 292,170 | SH |
| 5 | VERACYTE INC | VCYT | 92337F107 | $41.3M | 4.72% | 980,391 | SH |
| 6 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $40.1M | 4.59% | 420,773 | SH |
| 7 | WATERS CORP | WAT | 941848103 | $39.9M | 4.57% | 105,167 | SH |
| 8 | BROOKDALE SR LIVING INC | BKD | 112463104 | $37.7M | 4.31% | 3,491,663 | SH |
| 9 | ELI LILLY & CO | LLY | 532457108 | $37.7M | 4.31% | 35,045 | SH |
| 10 | BRUKER CORP | BRKR | 116794108 | $37.4M | 4.28% | 794,380 | SH |
| 11 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $34.9M | 3.99% | 76,910 | SH |
| 12 | CVS HEALTH CORP | CVS | 126650100 | $34.3M | 3.92% | 432,457 | SH |
| 13 | FORTREA HLDGS INC | FTRE | 34965K107 | $34.3M | 3.92% | 1,986,333 | SH |
| 14 | MERIT MED SYS INC | MMSI | 589889104 | $34.0M | 3.89% | 385,660 | SH |
| 15 | BRIGHTSPRING HEALTH SVCS INC | BTSG | 10950A106 | $33.6M | 3.84% | 897,427 | SH |
| 16 | DOXIMITY INC | DOCS | 26622P107 | $30.4M | 3.48% | 686,568 | SH |
| 17 | BIO-TECHNE CORP | TECH | 09073M104 | $27.5M | 3.14% | 467,409 | SH |
| 18 | ALPHATEC HLDGS INC | ATEC | 02081G201 | $27.1M | 3.09% | 1,285,685 | SH |
| 19 | ADAPTHEALTH CORP | AHCO | 00653Q102 | $26.0M | 2.97% | 2,609,003 | SH |
| 20 | ENVISTA HOLDINGS CORPORATION | NVST | 29415F104 | $25.8M | 2.95% | 1,186,704 | SH |
| 21 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $23.1M | 2.65% | 70,126 | SH |
| 22 | ABBOTT LABS | ABT | 002824100 | $22.0M | 2.51% | 175,333 | SH |
| 23 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $16.2M | 1.85% | 467,484 | SH |
| 24 | BIOHAVEN LTD | BHVN | G1110E107 | $10.8M | 1.24% | 958,336 | SH |
| 25 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $10.5M | 1.20% | 233,688 | SH |
| 26 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $9.5M | 1.09% | 230,730 | SH |
| 27 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $9.3M | 1.07% | 257,085 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2025-12-31 | 2026-02-17 | $874.7M | 27 | 0001172661-26-000928 |
| 2025-09-30 | 2025-11-14 | $703.3M | 25 | 0001172661-25-004856 |